CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

3.61 -3.73

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.57

Max

3.82

Galvenie mērījumi

By Trading Economics

Ienākumi

8.3M

-18M

Pārdošana

9.6M

10M

P/E

Sektora vidējais

22.5

56.269

EPS

-0.1

Peļņas marža

-177.89

Darbinieki

69

EBITDA

9.5M

-18M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+215.47% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-162M

748M

Iepriekšējā atvēršanas cena

7.34

Iepriekšējā slēgšanas cena

3.61

Ziņu noskaņojums

By Acuity

50%

50%

123 / 342 Rangs Healthcare

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. jūn. 23:36 UTC

News
Social Media

MercadoLibre Inc. shares declined in after-market trading following news of a securities fraud investigation related to loan term disclosures, raising investor concerns.

2026. g. 30. jūn. 23:36 UTC

News
Correlated Moves
Macro News
ETF Constituents

Vanguard Information Technology ETF's performance has been roughly flat during after-market hours, following a positive environment for technology stocks and the Nasdaq's rebound.

2026. g. 30. jūn. 23:26 UTC

News
Correlated Moves

iShares iBoxx $ Investment Grade Corporate Bond ETF trades lower in after-market hours, amid a broader decline in U.S. equity indices and technology stocks.

2026. g. 30. jūn. 23:21 UTC

News
Social Media

Micron Technology shares rose after hours, buoyed by a $250 million investment and significant revenue growth linked to AI chipmakers.

2026. g. 30. jūn. 23:11 UTC

News

Comcast Corp shares rose in after-market trading, continuing an upward trend. The company's market cap now exceeds that of American Tower, ranking 135th in the S&P 500.

2026. g. 30. jūn. 23:06 UTC

News
Correlated Moves

The US 10Y Treasury Bond Index is near unchanged in after-market hours, following a slight increase earlier in the day. The iShares 7-10 Year Treasury Bond ETF mirrors this stability.

2026. g. 30. jūn. 23:06 UTC

Social Media
News

Microsoft shares rise in after-market hours, driven by strength in the Systems Software sub-sector and a new partnership with Chevron for a natural gas facility.

2026. g. 30. jūn. 23:02 UTC

Social Media
News

Tesla Inc. shares are lower in after-market hours following Michael Burry's short position disclosure and a fatal incident involving one of its vehicles.

2026. g. 30. jūn. 23:02 UTC

News

The iShares 20+ Year Treasury Bond ETF is lower in after-market trading, reflecting broader declines in U.S. indices and mixed market conditions.

2026. g. 30. jūn. 23:02 UTC

News
ETF Constituents

Vanguard Growth ETF declines in after-market trading, driven by losses in top holdings NVIDIA, Tesla, and Meta, despite slight gains in the Nasdaq 100 Index.

2026. g. 30. jūn. 23:01 UTC

News

Fox Corp has secured a $1 billion loan to fund its Roku acquisition. Shares are higher in after-market hours, aided by a strong Broadcasting sector.

2026. g. 30. jūn. 22:51 UTC

News

Vanguard Total Bond Market ETF is lower in after-market hours, reflecting broader market pullbacks amid geopolitical tensions and fluctuating oil prices.

2026. g. 30. jūn. 20:08 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline. Sharplink's acquisition of 10,000 ETH at $1,611 has not prevented the drop.

2026. g. 30. jūn. 20:07 UTC

News

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

2026. g. 30. jūn. 20:07 UTC

Social Media
News

Intel Corp shares are advancing, driven by bullish semiconductor activity and increased buying interest. The stock reached a post-alert high of $131.14.

2026. g. 30. jūn. 20:07 UTC

News
Correlated Moves
Social Media

NVIDIA shares rose following SemiAnalysis's bullish projection for data center revenue, expected to exceed consensus by 20% in fiscal 2027's second half.

2026. g. 30. jūn. 20:07 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline and broader market pressures. Earlier, it dipped to a session low of $1,611.

2026. g. 30. jūn. 20:03 UTC

News
Correlated Moves
Social Media

Apple Inc. shares are higher after the Supreme Court agreed to hear its appeal in the Epic Games antitrust case, potentially benefiting App Store fees.

2026. g. 30. jūn. 20:03 UTC

News
Correlated Moves
Social Media

Analyst raises AMD price target to $615, citing strong AI demand. Shares are trading higher since Monday, reflecting positive market sentiment.

2026. g. 30. jūn. 20:03 UTC

Social Media
Correlated Moves
ETF Constituents
News

Invesco QQQ Trust Series I advances today, driven by positive technology sector sentiment and strong performance from major contributors like AMD and Apple.

2026. g. 30. jūn. 20:03 UTC

News
ETF Constituents

Health Care Select Sector SPDR Fund declines as health care underperforms, with Eli Lilly and Stryker contributing to the negative performance during Tuesday's session.

2026. g. 30. jūn. 20:03 UTC

Correlated Moves
News
ETF Constituents

Germany's retail sales rose 1.1% in May, exceeding expectations. The iShares MSCI Germany ETF is gaining, supported by strong performances from key holdings.

2026. g. 30. jūn. 20:02 UTC

Correlated Moves
Social Media
News

Applied Materials shares are higher today following price target increases, including Susquehanna's raise to $900 from $575, reflecting strong analyst sentiment.

2026. g. 30. jūn. 20:01 UTC

News

Expedia Group Inc shares are lower today amid a decline in the Hotels, Resorts & Cruise Lines sector. Wells Fargo cut its price target to $303.

2026. g. 30. jūn. 20:01 UTC

News

ASML Holding NV shares are higher amid positive sentiment and Bernstein's price target increase, supported by $518 billion in semiconductor infrastructure investments.

2026. g. 30. jūn. 20:01 UTC

News
Correlated Moves

Intuitive Surgical shares are lower, reaching a four-week low amid declines in the Health Care Equipment sub-sector and volatility in the market.

2026. g. 30. jūn. 20:01 UTC

News
Social Media

Illumina Inc shares are lower as Roche launches a competing gene sequencer at a lower price, challenging Illumina's market share in genetic testing technology.

2026. g. 30. jūn. 19:56 UTC

News

Henry Schein announced a partnership with GoTu Technology to enhance dental workforce support, though shares are lower during Tuesday's session.

2026. g. 30. jūn. 19:56 UTC

News
Correlated Moves

Concerns over currency volatility arise as the yen weakens against the dollar. EUR/HKD remains roughly flat since Monday's close amid broader market dynamics.

2026. g. 30. jūn. 19:52 UTC

News

Costco Wholesale shares are lower, reaching a four-week low of $938.50, amid declines in the Consumer Staples Merchandise Retail sub-sector.

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

215.47% augšup

Prognoze 12 mēnešiem

Vidējais 11.83 USD  215.47%

Augstākais 16 USD

Zemākais 6 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

6

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

123 / 342 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat